IntraBio announces plans for a multi-national randomised clinical trial to evaluate IB1000 as a therapeutic intervention for patients with NP-C
IntraBio is an Oxfordshire based clinical stage biopharmacuetical company developing treatments for rare lysosomal storage disorders including ASMD Niemann-Pick diseases (types A and B) and Niemann-Pick type C.
The Company has recently been granted Orphan Medicinal Product Designation by the European Medicines Agency (EMA) for two drugs, including IB1000 for the treatment of Niemann-Pick Types A, B & C diseases.
This week, Intrabio has announced plans for a multi-national randomized, controlled pivotal clinical trials to evaluate IB1000 as a therapeutic intervention in patients with NPC, For further information, please see the full announcement here.
